TY - JOUR
T1 - Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG)
T2 - A Randomized, Double-Blind, Placebo-Controlled Trial
AU - Willemsen, Laura M.
AU - Janssen, Paul W.A.
AU - Peper, Joyce
AU - Soliman-Hamad, Mohamed A.
AU - van Straten, Albert H.M.
AU - Klein, Patrick
AU - Hackeng, Chris M.
AU - Sonker, Uday
AU - Bekker, Margreet W.A.
AU - von Birgelen, Clemens
AU - Brouwer, Marc A.
AU - van der Harst, Pim
AU - Vlot, Eline A.
AU - Deneer, Vera H.M.
AU - Chan Pin Yin, Dean R.P.P.
AU - Gimbel, Marieke E.
AU - Beukema, Kasper F.
AU - Daeter, Edgar J.
AU - Kelder, Johannes C.
AU - Tijssen, Jan G.P.
AU - Rensing, Benno J.W.M.
AU - van Es, Hendrik W.
AU - Swaans, Martin J.
AU - Ten Berg, Jurrien M.
N1 - Publisher Copyright:
© 2020 American Heart Association, Inc.
PY - 2020/11/10
Y1 - 2020/11/10
N2 - BACKGROUND: Approximately 15% of saphenous vein grafts (SVGs) occlude during the first year after coronary artery bypass graft surgery (CABG) despite aspirin use. The POPular CABG trial (The Effect of Ticagrelor on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting Surgery) investigated whether ticagrelor added to standard aspirin improves SVG patency at 1 year after CABG. METHODS: In this investigator-initiated, randomized, double-blind, placebo-controlled, multicenter trial, patients with ≥1 SVGs were randomly assigned (1:1) after CABG to ticagrelor or placebo added to standard aspirin (80 or 100 mg). The primary outcome was SVG occlusion at 1 year, assessed with coronary computed tomography angiography, in all patients who had primary outcome imaging available. A generalized estimating equation model was used to perform the primary analysis per SVG. The secondary outcome was 1-year SVG failure, which was a composite of SVG occlusion, SVG revascularization, myocardial infarction in myocardial territory supplied by a SVG, or sudden death. RESULTS: Among 499 randomized patients, the mean age was 67.9±8.3 years, 87.1% were male, the indication for CABG was acute coronary syndrome in 31.3%, and 95.2% of procedures used cardiopulmonary bypass. Primary outcome imaging was available in 219 patients in the ticagrelor group and 224 patients in the placebo group. The SVG occlusion rate in the ticagrelor group was 9.6% (44 of 457 SVGs) versus 10.1% in the placebo group (50 of 497 SVGs; odds ratio, 0.87 [95% CI, 0.49-1.55]; P=0.64). SVG failure occurred in 32 patients (12.9%) in the ticagrelor group versus 32 patients (13.0%) in the placebo group (hazard ratio, 1.04 [95% CI, 0.63-1.69]). CONCLUSIONS: In this randomized, placebo-controlled trial, the addition of ticagrelor to standard aspirin did not reduce SVG occlusion at 1 year after CABG.
AB - BACKGROUND: Approximately 15% of saphenous vein grafts (SVGs) occlude during the first year after coronary artery bypass graft surgery (CABG) despite aspirin use. The POPular CABG trial (The Effect of Ticagrelor on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting Surgery) investigated whether ticagrelor added to standard aspirin improves SVG patency at 1 year after CABG. METHODS: In this investigator-initiated, randomized, double-blind, placebo-controlled, multicenter trial, patients with ≥1 SVGs were randomly assigned (1:1) after CABG to ticagrelor or placebo added to standard aspirin (80 or 100 mg). The primary outcome was SVG occlusion at 1 year, assessed with coronary computed tomography angiography, in all patients who had primary outcome imaging available. A generalized estimating equation model was used to perform the primary analysis per SVG. The secondary outcome was 1-year SVG failure, which was a composite of SVG occlusion, SVG revascularization, myocardial infarction in myocardial territory supplied by a SVG, or sudden death. RESULTS: Among 499 randomized patients, the mean age was 67.9±8.3 years, 87.1% were male, the indication for CABG was acute coronary syndrome in 31.3%, and 95.2% of procedures used cardiopulmonary bypass. Primary outcome imaging was available in 219 patients in the ticagrelor group and 224 patients in the placebo group. The SVG occlusion rate in the ticagrelor group was 9.6% (44 of 457 SVGs) versus 10.1% in the placebo group (50 of 497 SVGs; odds ratio, 0.87 [95% CI, 0.49-1.55]; P=0.64). SVG failure occurred in 32 patients (12.9%) in the ticagrelor group versus 32 patients (13.0%) in the placebo group (hazard ratio, 1.04 [95% CI, 0.63-1.69]). CONCLUSIONS: In this randomized, placebo-controlled trial, the addition of ticagrelor to standard aspirin did not reduce SVG occlusion at 1 year after CABG.
KW - coronary artery bypass
KW - saphenous vein
KW - ticagrelor
KW - vascular patency
UR - http://www.scopus.com/inward/record.url?scp=85095968934&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.120.050749
DO - 10.1161/CIRCULATIONAHA.120.050749
M3 - Article
C2 - 32862716
AN - SCOPUS:85095968934
SN - 0009-7322
VL - 142
SP - 1799
EP - 1807
JO - Circulation
JF - Circulation
IS - 19
ER -